Literature DB >> 26913791

Mortality, hospitalisation, institutionalisation in community-dwelling oldest old: The impact of medication.

Maarten Wauters1, Monique Elseviers2, Bert Vaes3, Jan Degryse3, Robert Vander Stichele2, Thierry Christiaens2, Majda Azermai2.   

Abstract

BACKGROUND: High drug use and associated adverse outcomes are common in older adults. This study investigates association of medication use with mortality, hospitalisation, and institutionalisation in a cohort of community-dwelling oldest old (aged 80 and over).
METHODS: Baseline data included socio-demographic, clinical, and functional characteristics, and prescribed medications. Medications were coded by the Anatomic Therapeutic Chemical classification. Survival analysis was performed at 18 months after inclusion using Kaplan-Meier, and multivariate analysis with Cox regression to control for covariates.
RESULTS: Patients' (n=503) mean age was 84.4 years (range 80-102), and 61.2% was female. The median medication use was 5 (0-16). The mortality, hospitalisation, and institutionalisation rate were 8.9%, 31.0%, and 6.4% respectively. The mortality and hospitalisation group had a higher level of multimorbidity and weaker functional profile. Adjusted multivariate models showed an 11% increased hospitalisation rate for every additional medication taken. No association was found between high medication use and mortality, nor with institutionalisation. A higher association for mortality was observed among verapamil/diltiazem users, hospitalisation was higher among users of verapamil/diltiazem, loop diuretics and respiratory agents. Institutionalisation was higher among benzodiazepines users.
CONCLUSION: In the community-dwelling oldest old (aged 80 and over), high medication was clearly associated with hospitalisation, independent of multimorbidity. The association with mortality was clear in univariate, but not in multivariate analysis. No association with institutionalisation was found. The appropriateness of the high medication use should be further studied in relation to mortality, hospitalisation, and institutionalisation for this specific age group.
Copyright © 2016 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Aged, 80 and over; Drug utilization; Hospitalization; Institutionalization; Mortality; Primary health care

Mesh:

Year:  2016        PMID: 26913791     DOI: 10.1016/j.archger.2016.02.009

Source DB:  PubMed          Journal:  Arch Gerontol Geriatr        ISSN: 0167-4943            Impact factor:   3.250


  10 in total

1.  Too many, too few, or too unsafe? Impact of inappropriate prescribing on mortality, and hospitalization in a cohort of community-dwelling oldest old.

Authors:  Maarten Wauters; Monique Elseviers; Bert Vaes; Jan Degryse; Olivia Dalleur; Robert Vander Stichele; Thierry Christiaens; Majda Azermai
Journal:  Br J Clin Pharmacol       Date:  2016-08-03       Impact factor: 4.335

2.  Exploring the practical application of the concept of frailty in pharmacy practice.

Authors:  Lori Blain; Priti Flanagan
Journal:  Can Pharm J (Ott)       Date:  2017-11-20

3.  Sarcopenia as a predictor of all-cause mortality among older nursing home residents: a systematic review and meta-analysis.

Authors:  Xiaoming Zhang; Conghua Wang; Qingli Dou; Wenwu Zhang; Yunzhi Yang; Xiaohua Xie
Journal:  BMJ Open       Date:  2018-11-12       Impact factor: 2.692

4.  Mortality in older adults with frequent alcohol consumption and use of drugs with addiction potential - The Nord Trøndelag Health Study 2006-2008 (HUNT3), Norway, a population-based study.

Authors:  Kjerstin Tevik; Geir Selbæk; Knut Engedal; Arnfinn Seim; Steinar Krokstad; Anne-S Helvik
Journal:  PLoS One       Date:  2019-04-16       Impact factor: 3.240

5.  Impact of a Pharmacist-included Mobile Geriatrics team intervention on potentially inappropriate drug prescribing: protocol for a prospective feasibility study (PharMoG study).

Authors:  Arnaud Pagès; Christel Roland; Soraya Qassemi; Anne-Bahia Abdeljalil; Mathieu Houles; Marjolaine Romain; Olivier Toulza; Audrey Belloc; Cécile McCambridge; Thierry Voisin; Philippe Cestac; Blandine Juillard-Condat
Journal:  BMJ Open       Date:  2020-12-02       Impact factor: 2.692

6.  A multidimensional measure of polypharmacy for older adults using the Health and Retirement Study.

Authors:  Ewan Carr; Alex Federman; Olubanke Dzahini; Richard J Dobson; Rebecca Bendayan
Journal:  Sci Rep       Date:  2021-04-22       Impact factor: 4.379

7.  Comparing the Clinical Characteristics and Mortality of Residential and Non-Residential Older People with COVID-19: Retrospective Observational Study.

Authors:  Francesc X Marin-Gomez; Jacobo Mendioroz-Peña; Miguel-Angel Mayer; Leonardo Méndez-Boo; Núria Mora; Eduardo Hermosilla; Ermengol Coma; Josep-Maria Vilaseca; Angela Leis; Manolo Medina; Queralt Miró Catalina; Josep Vidal-Alaball
Journal:  Int J Environ Res Public Health       Date:  2022-01-02       Impact factor: 3.390

8.  Is polypharmacy associated with mortality in the very old: Findings from the Newcastle 85+ Study.

Authors:  Laurie E Davies; Andrew Kingston; Adam Todd; Barbara Hanratty
Journal:  Br J Clin Pharmacol       Date:  2022-01-27       Impact factor: 3.716

9.  Multidrug use positively correlates with high-risk prescriptions in the Japanese elderly: a longitudinal study.

Authors:  Sayaka Arai; Takahiro Ishikawa; Hisaya Kato; Masaya Koshizaka; Yoshio Maezawa; Takako Nakamura; Takaaki Suzuki; Koutaro Yokote; Itsuko Ishii
Journal:  J Pharm Health Care Sci       Date:  2019-09-02

10.  Polypharmacy and mortality association by chronic kidney disease status: The REasons for Geographic And Racial Differences in Stroke Study.

Authors:  Winn Cashion; William McClellan; Suzanne Judd; Abhinav Goyal; David Kleinbaum; Michael Goodman; Valerie Prince; Paul Muntner; George Howard
Journal:  Pharmacol Res Perspect       Date:  2021-08
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.